M35.4 Diffuse (eosinophilic) fasciitis

Name of the Condition

• Diffuse (Eosinophilic) Fasciitis
• Medical Term: Eosinophilic Fasciitis

Summary

Diffuse (eosinophilic) fasciitis is a rare connective tissue disorder characterized by inflammation and thickening of the fascia, the fibrous tissue surrounding muscles. It often presents with skin induration, pain, and limited mobility, typically affecting the limbs and trunk. The condition may be associated with peripheral eosinophilia, a higher-than-normal level of eosinophils in the blood.

Causes

The exact cause is unknown, but it is thought to involve an abnormal immune response, possibly triggered by environmental factors (e.g., infections, medications, or physical trauma). Autoimmunity is suspected, as the body’s immune system appears to target the fascia, leading to inflammation and fibrosis.

Risk Factors

• Age: Most commonly diagnosed in adults, particularly those aged 40–60.
• Gender: Slightly more prevalent in males.
• Prior Infections or Trauma: Some cases follow viral infections or physical injury.
• Medication Exposure: Rarely linked to certain drugs, though causality is unclear.

Symptoms

• Progressive skin thickening and induration, often starting in the arms or legs.
• Joint pain and stiffness, particularly in the wrists, fingers, or ankles.
• Muscle weakness or fatigue.
• Peripheral eosinophilia (elevated eosinophil count in blood).
• Possible hyperpigmentation or edema in affected areas.

Diagnosis

Diagnosis is based on clinical evaluation, including a physical exam to assess skin and fascial changes. Laboratory tests may show elevated inflammatory markers or eosinophilia. Imaging (e.g., MRI) can reveal fascial thickening. A skin or fascial biopsy is often performed to confirm inflammation and fibrosis.

Treatment Options

• Corticosteroids: First-line therapy to reduce inflammation and fibrosis.
• Immunosuppressants: Used in refractory cases (e.g., methotrexate, azathioprine).
• Physical Therapy: To maintain mobility and manage stiffness.
• Symptom Management: Pain relievers or anti-inflammatory drugs for discomfort.

Prognosis and Follow-Up

Prognosis is generally favorable with early treatment, though some patients may experience persistent skin thickening or limited mobility. Regular follow-up is recommended to monitor for complications, such as contractures or organ involvement. Most patients respond to therapy, but relapses can occur.

Complications

• Contractures: Permanent joint stiffness due to fibrosis.
• Muscle Weakness: Prolonged inflammation may affect muscle function.
• Organ Involvement: Rarely, the condition may extend to internal organs (e.g., lungs, heart).
• Chronic Pain: Persistent discomfort in affected areas.

Lifestyle & Prevention

• Avoid Triggers: Minimize exposure to potential environmental triggers (e.g., certain medications, infections).
• Physical Activity: Gentle exercise to maintain flexibility and reduce stiffness.
• Skin Care: Moisturize to manage dryness or hyperpigmentation.
• Regular Monitoring: Follow up with a rheumatologist or dermatologist for ongoing care.

When to Seek Professional Help

Seek medical attention if you develop unexplained skin thickening, joint pain, or stiffness, especially if accompanied by fatigue or swelling. Prompt evaluation is important to initiate treatment and prevent complications.

Tips for Medical Coders

• Use code M35.4 for diffuse (eosinophilic) fasciitis.
• Document clinical findings (e.g., skin induration, eosinophilia) and diagnostic tests (e.g., biopsy, imaging) to support coding.
• Ensure differentiation from other connective tissue disorders (e.g., scleroderma) based on clinical presentation.
• Note any associated conditions (e.g., peripheral eosinophilia) as secondary diagnoses if applicable.